Altamofen Tablets (Generic Tamoxifen Citrate Tablets)

Altamofen Tablets (Generic Tamoxifen Citrate Tablets)
© The Swiss Pharmacy

Altamofen (Generic Tamoxifen Citrate Tablets) is used
for the treatment of breast cancer, the treatment of
anovulatory infertility and the primary prevention of
breast cancer in women at moderate or high risk.
This medication can block the growth of breast cancer.
It works by interfering with the effects of estrogen in the
breast tissue.

Altamofen Tablets are
manufactured by Alpha Pharma
Healthcare Private limited, India in
the strength of 20 mg.

Chemical Structure

The active ingredient contained in
Altamofen tablets is Tamoxifen Citrate.
Each 20 mg tablet of Altamofen contains
30.4 mg of Tamoxifen Citrate which is
equivalent to 20 mg of Tamoxifen.

Uses of Altamofen 20 mg Tablets:
Tamoxifen Tablets are used to treat breast cancer.
Tamoxifen citrate tablets are effective in the treatment of estrogen
receptor-positive metastatic breast cancer in women and men.
Tamoxifen Citrate tablets are indicated for the treatment of node-
positive breast cancer in postmenopausal women following total
mastectomy or segmental mastectomy, axillary dissection, and
breast irradiation.
In women with DCIS, following breast surgery and radiation,
Tamoxifen Citrate tablets are indicated to reduce the risk of invasive
breast cancer .
For adjuvant treatment of adult patients with early stage estrogen
receptor-positive breast cancer
URL: https://www.theswisspharmacy.com/product_info.php?info=p9948_Altamofen-Tablets.html

Uses of Altamofen 20 mg Tablets:
Altamofen (Generic Tamoxifen Citrate Tablets) are also used to treat
infertility in women caused by a failure to produce and release eggs
(ovulate) properly.
Tamoxifen Citrate Tablets can also reduce the risk of developing
breast cancer occurring in those women who have an increased
likelihood of developing breast cancer (your risk).
It is important that your healthcare professional calculates your risk of
developing breast cancer and discusses the result with you before
commencing treatment.

How Does Altamofen 20 mg Tablets Work?
Tamoxifen blocks the effects of estrogen — a reproductive hormone
that influences the growth and development of many breast cancers.
Tamoxifen belongs to a class of drugs known as selective estrogen
receptor modulators (SERMs). The drug reduces the effects of
estrogen in most areas of the body, including the breast. In the uterus,
however, Tamoxifen acts like an estrogen and encourages the
growth of the lining of the uterus.
Tamoxifen is usually prescribed as a pill taken once a day by mouth.
For breast cancer risk reduction, tamoxifen is typically taken for a
total of five years. The risk reduction benefit continues for five
additional years after you stop taking Tamoxifen.

Recommended Adult Dosage
Breast Cancer: For patients with breast cancer, the recommended
daily dose of Altamofen Tablets (Generic Tamoxifen Tablets) is
20 mg to 40 mg.
Dosages greater than 20 mg per day should be given in divided
doses (morning and evening).
Ductal Carcinoma in Situ (DCIS): The recommended dose is 20 mg
of Altamofen daily for 5 years.
Reduction in Breast Cancer Incidence in High Risk Women: The
recommended dose is 20 mg of Altamofen daily for 5 years.

Recommended Adult Dosage
Infertility (Anovulatory Disorders): The possibility of pregnancy must
be excluded before the commencement of treatment, whether initial
or subsequent. The recommended dosage of Altamofen Tablets
(Tamoxifen Citrate) iIn women with regular menstruation but with
anovular cycles, treatment should commence with 20 mg daily in
either one or two doses administered on the second, third, fourth and
fifth days of the menstrual cycle. In unsuccessful cases further
courses may be given during subsequent menstrual periods,
increasing the dosage to 20 mg then 40 mg twice daily.
In women with irregular menstruation, the commencement of
treatment may take place on any day. If this initial course is
not successful then a further course may be initiated after an interval
of 45 days with the higher dosage level (20 mg to 40 mg twice daily).

Contraindications
➔
Altamofen is contraindicated in patients with a known
hypersensitivity to Tamoxifen Citrate or any component of the
tablet.
➔
Pre-menopausal patients must be carefully examined before
treatment for all indications to exclude the possibility of
pregnancy.
➔
Concurrent Anastrozole therapy is contraindicated.

Contraindications
➔
For the treatment for infertility, Tamoxifen should not be used in
patients with a personal or family history of confirmed idiopathic
venous thromboembolic events or a known genetic defect.
➔
For the indication of primary prevention of breast cancer,
Tamoxifen should not be used in Women with a history of deep
vein thrombosis or pulmonary embolus and women who require
concomitant coumarin-type anticoagulant therapy.

Storage Instructions
Altamofen (Generic Tamoxifen Citrate Tablets) have
to be stored at controlled room temperature i.e. from
20°C to 25°C (68°F to 77°F) with excursions permitted
between 15° to 30°C (59° to 86°F).
Keep this as well as all other medicines away from
children and pets.

Warnings
There is evidence of an increased incidence of thromboembolic
events, including deep vein thrombosis and pulmonary embolism,
during tamoxifen therapy. Risk of thromboembolic effects increases
with coadministered chemotherapy. For treatment of breast cancer,
consider risks and benefits in patients with a history of thromboembolic
events.
In the Swedish trial using adjuvant Tamoxifen 40 mg/day for 2-5 years,
3 cases of liver cancer have been reported in the tamoxifen-treated
group vs. 1 case in the observation group. In other clinical trials
evaluating tamoxifen, no cases of liver cancer have been reported to
date.
One case of liver cancer was reported in NSABP P-1 in a participant
randomized to Tamoxifen.

Warnings
Tamoxifen has been associated with changes in liver enzyme levels,
and on rare occasions, a spectrum of more severe liver abnormalities
including fatty liver, cholestasis, hepatitis and hepatic necrosis.
A number of second primary tumors, occurring at sites other than the
endometrium, have been reported following the treatment of breast
cancer with Tamoxifen in clinical trials.
Can cause fetal harm. Advise females of reproductive potential of the
potential risk to a fetus and to use effective contraception.

Warnings
Ocular disturbances, including corneal changes, decrement in
color vision perception, retinal vein thrombosis, and retinopathy
have been reported in patients receiving Tamoxifen. An
increased incidence of cataracts and the need for cataract
surgery have been reported in patients receiving Tamoxifen.

Possible Side Effects
In patients treated with Tamoxifen Citrate Tablets (Altamofen) for
metastatic breast cancer, the most frequent side effect to Tamoxifen
is hot flashes.
Other side effects which are seen infrequently are hypercalcemia,
peripheral edema, distaste for food, pruritus vulvae, depression,
dizziness, light-headedness, headache, hair thinning and/or partial
hair loss, and vaginal dryness.

Overdosage
Acute overdosage of Tamoxifen Citrate Tablets (Altamofen) in
humans has not been reported. In a study of advanced metastatic
cancer patients which specifically determined the maximum tolerated
dose of Tamoxifen tablets in evaluating the use of very high doses to
reverse multidrug resistance, acute neurotoxicity manifested by
tremor, hyperreflexia, unsteady gait and dizziness were noted. These
symptoms occurred within 3 to 5 days of beginning Tamoxifen and
cleared within 2 to 5 days after stopping therapy. No permanent
neurologic toxicity was noted. No specific treatment for Tamoxifen
Citrate overdosage is known and treatment must be symptomatic.

Altamofen Tablets During Pregnancy
Tamoxifen Citrate (Altamofen Tablets) has been classified by
the US FDA as Pregnancy Category D.
Tamoxifen Tablets (Altamofen) may cause fetal harm when
administered to a pregnant woman.
Women should be advised not to become pregnant while taking
Altamofen or within 2 months of discontinuing Altamofen and
should use barrier or nonhormonal contraceptive measures if
sexually active.

Altamofen Tablets During Pregnancy
There have been a small number of reports of vaginal
bleeding, spontaneous abortions, birth defects, and fetal
deaths in pregnant women.
If this medicine is used during pregnancy, or the patient
becomes pregnant while taking this medication, or within
approximately two months after discontinuing therapy, the
patient should be apprised of the potential risks to the fetus
including the potential long-term risk of a DES-like syndrome.

Altamofen Tablets (Generic Tamoxifen Citrate
Tablets) are manufactured by Alpha Pharma
Healthcare Private limited, India.

Altamofen Tablets (Generic Tamoxifen Citrate Tablets)

Recommended

Recommended

More Related Content

Similar to Altamofen Tablets (Generic Tamoxifen Citrate Tablets)

Similar to Altamofen Tablets (Generic Tamoxifen Citrate Tablets) (20)

More from The Swiss Pharmacy

More from The Swiss Pharmacy (20)

Recently uploaded

Recently uploaded (20)

Altamofen Tablets (Generic Tamoxifen Citrate Tablets)